| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
| Targets |
3-Methyl-L-histidine does not have a specific pharmacological receptor target. As a naturally occurring amino acid metabolite, it is primarily used as a biomarker for muscle protein breakdown. The compound is released during the degradation of actin and myosin, and its urinary excretion reflects the rate of muscle protein turnover. It is not incorporated into proteins and is not reutilized for protein synthesis.
|
|---|---|
| ln Vitro |
In vitro, 3-methyl-L-histidine can be measured in cell culture media, tissue extracts, and biological fluids as a marker of protein breakdown. The compound can be quantified using HPLC, LC-MS, or amino acid analysis. It is not typically used for biological activity assays but serves as an analytical standard and biomarker.
|
| ln Vivo |
In vivo, 3-methyl-L-histidine is present in plasma and urine. Its concentration reflects muscle protein breakdown and turnover. It is used as a diagnostic and monitoring tool for conditions affecting muscle metabolism, including muscle wasting, sarcopenia, and nutritional deficiencies. The compound is excreted in the urine and can be measured to assess protein catabolism.
|
| Enzyme Assay |
For non-cellular assays, 3-methyl-L-histidine is used as a standard for analytical method development and validation. It can be used in enzyme assays to measure the activity of enzymes involved in histidine methylation or protein degradation.
|
| Cell Assay |
For in vitro cell-based assays, cells that produce contractile proteins (such as muscle cells) can be cultured, and 3-methyl-L-histidine can be measured in the culture media as a marker of protein breakdown. The effects of drugs or toxins on muscle protein turnover can be assessed.
|
| Animal Protocol |
For in vivo animal studies, 3-methyl-L-histidine levels can be measured in plasma and urine to assess muscle protein breakdown. Animal models of muscle wasting, cachexia, and aging can be studied. The effects of nutritional interventions, exercise, and pharmacological agents on muscle protein turnover can be evaluated.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3-methyl-L-histidine include solubility in water and dilute acid. It is a small molecule and is readily excreted in the urine. It is a metabolite and is not typically administered as a drug.
|
| Toxicity/Toxicokinetics |
As a naturally occurring metabolite, 3-methyl-L-histidine is generally considered safe. No significant toxicity has been reported at physiological concentrations.
|
| Additional Infomation |
N-(precursor)-methyl-L-histidine is a derivative of L-histidine, with a methyl group substituted at the 3-position of its imidazole ring. It is a metabolite in both humans and Saccharomyces cerevisiae. It is an L-histidine derivative and a non-protein L-α-amino acid. It is a zwitterionic tautomer of N-(proline)-methyl-L-histidine. 3-methyl-L-histidine has been reported to exist in Apis cerana, Trypanosoma brucei, and Caenorhabditis elegans, with supporting data. 3-Methylhistidine is a post-translational modified amino acid found in actin and myosin, and is a derivative of histidine with a methyl group attached to the nitrogen atom at the 3-position. The level of 3-methylhistidine in urine is directly proportional to protein turnover and can be used as an indicator of myofibrillar protein degradation or a high-protein diet.
3-Methyl-L-histidine is a naturally occurring methylated amino acid derivative. It is formed by the methylation of histidine residues in actin and myosin. It is a useful biomarker for muscle protein breakdown. It is excreted in the urine and can be measured to assess protein catabolism. |
| Molecular Formula |
C7H11N3O2
|
|---|---|
| Molecular Weight |
169.18114
|
| Exact Mass |
169.085
|
| CAS # |
368-16-1
|
| PubChem CID |
64969
|
| Appearance |
White to off-white solid powder
|
| Density |
1.37g/cm3
|
| Boiling Point |
415ºC at 760mmHg
|
| Flash Point |
204.8ºC
|
| Index of Refraction |
1.613
|
| Source |
Endogenously produced metabolite: Disease markers Endocrine diseases
Endogenously produced metabolite: Disease markers Nervous System Disorder Endogenously produced metabolite: Disease markers Cardiovascular System Disorder |
| LogP |
0.01
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
174
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN1C=NC=C1C[C@@H](C(=O)O)N
|
| InChi Key |
JDHILDINMRGULE-LURJTMIESA-N
|
| InChi Code |
InChI=1S/C7H11N3O2/c1-10-4-9-3-5(10)2-6(8)7(11)12/h3-4,6H,2,8H2,1H3,(H,11,12)/t6-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(3-methylimidazol-4-yl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~591.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (295.54 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9109 mL | 29.5543 mL | 59.1086 mL | |
| 5 mM | 1.1822 mL | 5.9109 mL | 11.8217 mL | |
| 10 mM | 0.5911 mL | 2.9554 mL | 5.9109 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
